RESUMEN
The fixed-dose combination fluticasone propionate/formoterol (FPF) is a novel combination of a widely known and used inhaled glucocorticoid (IGC) and a long-acting ß2-adrenergic agonist (LABA), available for the first time in a single device. This fixed-dose combination of FPF has a demonstrated efficacy and safety profile in clinical trials compared with its individual components and other fixed-dose combinations of IGC/LABA and is indicated for the treatment of persistent asthma in adults and adolescents. FPF is available in a wide range of doses that can adequately cover the therapeutic steps recommended by treatment guidelines, constituting a fixed-dose combination of GCI/LABA that is effective, rapid, well tolerated and with a reasonable acquisition cost. Various assessment agencies of the Spanish Autonomous Communities consider this combination to be an appropriate alternative therapy for asthma in the primary care setting.
Asunto(s)
Androstadienos/uso terapéutico , Antiasmáticos/uso terapéutico , Asma/tratamiento farmacológico , Etanolaminas/uso terapéutico , Adolescente , Adulto , Androstadienos/administración & dosificación , Androstadienos/efectos adversos , Antiasmáticos/administración & dosificación , Antiasmáticos/efectos adversos , Relación Dosis-Respuesta a Droga , Combinación de Medicamentos , Etanolaminas/administración & dosificación , Etanolaminas/efectos adversos , Fluticasona , Fumarato de Formoterol , Glucocorticoides/administración & dosificación , Glucocorticoides/efectos adversos , Glucocorticoides/uso terapéutico , Humanos , Guías de Práctica Clínica como Asunto , Atención Primaria de Salud , EspañaRESUMEN
No disponible
Asunto(s)
Humanos , Antiasmáticos/uso terapéutico , Antiasmáticos/administración & dosificación , Dosificación/métodos , Asma/tratamiento farmacológicoRESUMEN
Results and complications of 100 consecutive thoracoscopies performed with local anesthesia, in our department of pneumology are reviewed. The group is constituted by 60 men and 40 women with an average age of 56.1 +/- 16.7 years (13-81). Age difference between tumoral (n = 58) and tuberculous patients (n = 13) was statistically significant (59.6 +/- 12.8 vs 39.3 +/- 18.7; p < 0.001). The most frequent symptom on presentation was dyspnea, an significant association was detected between fever and tuberculosis (p < 0.001). Final diagnosis were: tumor (n = 58), non-specific inflammation (n = 16), tuberculosis (n = 13), pneumothorax (n = 11) and pneumonia (n = 2). In 14 patients some complication of the procedure appeared, all of these had little clinical significance and were resolved with minimal nursing care. To diagnose tumor, macroscopic aspect showed a sensitivity of 96.1%, specificity of 86% and 92% assurance.